India Urology Drugs Market to Establish Growth with Impressive CAGR until FY2027

By | January 23, 2023

India Urology Drugs Market is expected to show robust growth due to increasing cases of prostate cancer in the forecast period, FY2017-FY2027.

According to TechSci report on, “India Urology Drugs Market, By Region, Competition Forecast & Opportunities, FY2017 – FY2027”, India urology drugs market has shown promising growth in historical years until FY2020 and is expected to continue its growth in upcoming forecast years FY2023 to FY2027. India urology drugs market owes its growth to the factors like rapidly increasing geriatric population of the country.

Geriatric population is more susceptible to urological diseases like Benign prostatic hyperplasia, overactive bladder, nocturia, etc. and with weak immune system their capability to recover also diminishes thereby creating surge in the demands for urology drugs and driving the growth of the India urology drugs market in the upcoming five years. Increasing instances of prostate cancer among the population is further supporting the growth of the India urology drugs market in the next five years.

Rapidly increasing number of UTI surgical procedures and demand for effective treatment is further substantiating the growth of the India urology drugs market in the future five years. Increasing instances of diabetes and obesity are also responsible for the increasing cases of urinary tract infection and thus substantiate the growth of the India urology drugs market in the future five years.

Increasing demand for the effective treatment and advanced pharmaceutical is also supporting the growth of the India urology drugs market in the forecast years, until FY2027. Moreover, factors like consistent research and technological advancement in the innovative therapeutic product development of urology drugs for regulating the conditions of the patients are further anticipated to support further growth of India urology drugs market in the forecast period.

Browse over XX market data Figures spread through 70 Pages and an in-depth TOC on “India Urology drugs Market”

https://www.techsciresearch.com/report/india-urology-drugs-market/8162.html

The India urology drugs market segmentation is based on drug class, type, application, distribution channel, competitional landscape, and regional distribution. Based on drug class, the market is further fragmented into anticholinergic/ antispasmodic agents, skeletal muscle relaxants, alpha blockers, and others. Anticholinergic/ Antispasmodic agents are the types of medicine that includes the natural belladonna alkaloids like atropine, belladonna, hyoscyamine, and scopolamine.

The drugs are used to relieve pain stimulus and spasms of the stomach, intestines, and bladder. Increasing demand for the painkillers for stomach pain, bladder pain etc. is further driving the growth of the sub-segment along with the growth of the India urology drugs market in the upcoming five years. The growth is anticipated to aid anticholinergic or antispasmodic agents to dominate the market segment and hold largest revenue shares of the market in the next five years.

Also based on type, the market is further divided between original drugs and generic drugs. Original drugs are anticipated to hold the largest revenue shares of the market and dominate the market segment in the upcoming five years on the account of increasing development of the pharmaceuticals as urology drugs. Multiple market players are actively investing in the research and advanced drug development for the increasing urological diseases thus aiding the growth of the India urology drugs market in the next five years.

Generic drugs are also anticipated to register significant growth in the subsequent years on the grounds of growing generic drugs industry. Feasibility and availability of the generic drugs as an OTC in the Indian pharmaceutical market further aids the growth of the India urology drugs market in the forecast years.

Based on application, the market is segmented into benign prostatic hyperplasia (BPH), prostate cancer, urinary incontinence, kidney/bladder stone, erectile dysfunction, and others. Prostate cancer is anticipated to lead the market segment in the next five years since the number of prostate cancers among male population of the country is rapidly increasing. Also, increasing geriatric population of the country is more risk prone to prostate cancer and thus drives the growth of the India urology drugs market in the upcoming five years.

A partial list of market players in the field includes:

·         Astellas Pharma India Pvt Ltd

·         Endo Pharmaceuticals

·         Sanofi India

·         Pfizer Ltd.

·         Innovexia Lifesciences

·         Salvus Pharma

·         Silhos Pharma Ltd.

Download Sample Report https://www.techsciresearch.com/sample-report.aspx?cid=8162

Customers can also request for 10% free customization on this report.

“Retail pharmacies are rapidly growing in the country and their revenue share is anticipated to be highest in the future five years and driving the growth of the India urology drugs market. Increasing instances of urology diseases and increasing demand for the efficient treatment urinary tract infectious diseases and other urological diseases with the availability of the affordable urology drugs are further anticipated to aid to the growth of the India urology drugs market in the next five years. Increasing investment from the governmental bodies and private investments toward research institutes is further expected to support market growth. New market players entering the market in the future may invest in extended research and innovative product development for their brand establishment. Partnerships and conjugation with the global giants dominating the market may support future market growth,” said Mr. Karan Chechi, Research Director with TechSci Research, a research based global management consulting firm.

India Urology Drugs Market By Drug Class (Anticholinergic/ Antispasmodic Agents, Skeletal Muscle Relaxants, Alpha Blockers, Others), By Type (Original Drugs v/s Generic Drugs), By Application (Benign Prostatic Hyperplasia (BPH), Prostate Cancer, Urinary Incontinence, Kidney/Bladder Stone, Erectile Dysfunction, Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online), By Region, Competition Forecast & Opportunities, FY2027 has evaluated the future growth potential of India urology drugs market and provides statistics & information on market size, structure and future market growth. The report intends to provide cutting-edge market intelligence and help decision makers take sound investment decisions. Besides, the report also identifies and analyzes the emerging trends along with essential drivers, challenges, and opportunities in India urology drugs market.

Contact

Mr. Ken Mathews

708 Third Avenue,

Manhattan, NY,

New York – 10017

Tel: +1-646-360-1656

Email: [email protected]

Website: https://www.techsciresearch.com